Angiotensin II receptor antagonism reverts the selective cardiac BNP upregulation and secretion observed in myocarditis

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 6, 2008, Pages

  Ogawa, Tsuneo ^a   Veinot, John P ^a   Kuroski De Bold, Mercedes L ^a   Georgalis, Tina ^a   De Bold, Adolfo J ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Atrial natriuretic factor; Brain natriuretic peptide; Cytokines

Indexed keywords

ALPHA CHEMOKINE; ANGIOTENSIN 2 RECEPTOR; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CYTOKINE; IMIDAZOLE DERIVATIVE; MESSENGER RNA; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GRAFT REJECTION; HISTOPATHOLOGY; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BLOOD; BLOOD PRESSURE; DISEASE MODEL; DRUG EFFECT; GENETICS; HEART MUSCLE; LEWIS RAT; METABOLISM; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; PATHOLOGY; POLYMERASE CHAIN REACTION; PROTEIN MICROARRAY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CYTOKINES; DISEASE MODELS, ANIMAL; IMIDAZOLES; MYCOBACTERIUM TUBERCULOSIS; MYOCARDITIS; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; POLYMERASE CHAIN REACTION; PROTEIN ARRAY ANALYSIS; RATS; RATS, INBRED LEW; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; TETRAZOLES; UP-REGULATION;

EID: 49249138845     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00215.2008     Document Type: Article

References (27)

1. Burjonroppa SC, Tong AT, Xiao LC, Johnson MM, Yusuf SW, Lenihan DJ. Cancer patients with markedly elevated B-type natriuretic peptide may not have volume overload. Am J Clin Oncol 30: 287-293, 2007.
2. Chandrasekar B, Smith JB, Freeman GL. Ischemia-reperfusion of rat myocardium activates nuclear factor-KappaB and induces neutrophil infiltration via lipopolysaccharide-induced CXC chemokine. Circulation 103: 2296-2302, 2001.
3. Damas JK, Aukrust P, Ueland T, Odegaard A, Eiken HG, Gullestad L, Sejersted OM, Christensen G. Monocyte chemoattractant protein-1 enhances and interleukin-10 suppresses the production of inflammatory cytokines in adult rat cardiomyocytes. Basic Res Cardiol 96: 345-352, 2001.
4. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110: 1103-1107, 2004.
5. Fuse K, Kodama M, Hanawa H, Okura Y, Ito M, Shiono T, Maruyama S, Hirono S, Kato K, Watanabe K, Aizawa Y. Enhanced expression and production of monocyte chemoattractant protein-1 in myocarditis. Clin Exp Immunol 124: 346-352, 2001.
6. George J, Patal S, Wexler D, Roth A, Sheps D, Keren G. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure. Am Heart J 150: 484-487, 2005.
7. Godsel LM, Leon JS, Engman DM. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in experimental myocarditis. Curr Pharm Des 9: 723-735, 2003.
8. Kobusiak-Prokopowicz M, Orzeszko J, Mazur G, Mysiak A, Orda A, Mazurek W. Kinetics of chemokines in acute myocardial infarction. Kardiol Pol 62: 301-314, 2005.
9. Kodama M, Hanawa H, Saeki M, Hosono H, Inomata T, Suzuki K, Shibata A. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 75: 278-284, 1994.
10. Li H, Simon H, Bocan TM, Peterson JT. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition. Cardiovasc Res 46: 298-306, 2000.
11. Li YY, McTiernan CF, Feldman AM. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res 42: 162-172, 1999.
12. Ma KK, Banas K, de Bold AJ. Determinants of inducible brain natriuretic peptide promoter activity. Regul Pept 128: 169-176, 2005.
13. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by proinflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 36: 505-513, 2004.
14. Maeda K, Shioi T, Kosugi R, Yoshida Y, Takahashi K, Machida Y, Izumi T. Rapamycin ameliorates experimental autoimmune myocarditis. Int Heart J 46: 513-530, 2005.
15. Masters RG, Davies RA, Veinot JP, Hendry PJ, Smith SJ, de Bold AJ. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 100: 287-291, 1999.
16. Nimata M, Kishimoto C, Yuan Z, Shioji K. Beneficial effects of olmesartan, a novel angiotensin II receptor type 1 antagonist, upon acute autoimmune myocarditis. Mol Cell Biochem 259: 217-222, 2004.
17. Ogawa T, Linz W, Stevenson M, Bruneau BG, Kuroski de Bold ML, Chen JH, Eid H, Scholkens BA, de Bold AJ. Evidence for loaddependant and load-independent determinants of cardiac natriuretic peptide production. Circulation 93: 2059-2067, 1996.
18. Ogawa T, Veinot JP, Davies RA, Haddad H, Smith SJ, Masters RG, Hendry PJ, Starling R, Kuroski de Bold ML, Ponce A, Ma KK, Williams K, de Bold AJ. Neuroendocrine profiling of humans receiving cardiac allografts. J Heart Lung Transplant 24: 1046-1054, 2005.
19. Okura Y, Yamamoto T, Goto S, Inomata T, Hirono S, Hanawa H, Feng L, Wilson CB, Kihara I, Izumi T, Shibata A, Aizawa Y, Seki S, Abo T. Characterization of cytokine and iNOS mRNA expression in situ during the course of experimental autoimmune myocarditis in rats. J Mol Cell Cardiol 29: 491-502, 1997.
20. Peterson JT, Li H, Dillon L, Bryant JW. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 46: 307-315, 2000.
21. Rudiger A, Gasser S, Fischler M, Hornemann T, von Eckardstein A, Maggiorini M. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure. Crit Care Med 34: 2140-2144, 2006.
22. Sandmann S, Li J, Fritzenkotter C, Spormann J, Tiede K, Fischer JW, Unger T. Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats. Blood Press 15: 116-128, 2006.
23. Schindler R, Dinarello CA, Koch KM. Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine 7: 526-533, 1995.
24. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ 3rd, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97: 1708-1715, 1998.
25. Yan AT, Yan RT, Spinale FG, Afzal R, Gunasinghe HR, Stroud RE, McKelvie RS, Liu PP. Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure. Eur J Heart Fail 10: 125-128, 2008.
26. Yokota N, Bruneau BG, Fernandez BE, Kuroski de Bold ML, Piazza LA, Eid H, de Bold AJ. Dissociation of cardiac hypertrophy, myosin heavy chain isoform expression, and natriuretic peptide production in DOCA-salt rats. Am J Hypertens 8: 301-310, 1995.
27. 1 antagonist, suppresses cytotoxic myocardial injury in autoimmune heart failure. Am J Physiol Heart Circ Physiol 289: H1147-H1152, 2005.